Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Gsk-461364. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PLK1 known ✓ | P53350 | 18/20 | 1.00 |
| ▸ | PLK3 | Q9H4B4 | 11/20 | 1.00 |
| ▸ | NEK2 | P51955 | 3/20 | 1.00 |
| ▸ | PIK3CD | O00329 | 2/20 | 1.00 |
| ▸ | PDGFRB | P09619 | 2/20 | 1.00 |
| ▸ | PIM1 | P11309 | 2/20 | 1.00 |
| ▸ | PIK3CG | P48736 | 2/20 | 1.00 |
| ▸ | PIK3C2B | O00750 | 1/20 | 1.00 |
| ▸ | RIOK3 | O14730 | 1/20 | 1.00 |
| ▸ | DAPK3 | O43293 | 1/20 | 1.00 |
| ▸ | PIP5K1C | O60331 | 1/20 | 1.00 |
| ▸ | RPS6KA4 | O75676 | 1/20 | 1.00 |
| ▸ | STK10 | O94804 | 1/20 | 1.00 |
| ▸ | PRKD3 | O94806 | 1/20 | 1.00 |
| ▸ | KIT | P10721 | 1/20 | 1.00 |
| ▸ | CSNK2A2 | P19784 | 1/20 | 1.00 |
| ▸ | GRK4 | P32298 | 1/20 | 1.00 |
| ▸ | TIE1 | P35590 | 1/20 | 1.00 |
| ▸ | FLT3 | P36888 | 1/20 | 1.00 |
| ▸ | PRKCI | P41743 | 1/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Gsk-461364 SCHEMBL29360650 | 1.00 | PLK1 (1.00) | PLK1PLK3NEK2PIK3CDPDGFRB | |
| Gsk-461364 SCHEMBL4276841 | 1.00 | PLK1 (1.00) | PLK1PLK3NEK2PIK3CDPDGFRB | |
| Gsk-461364 SCHEMBL310080 | 1.00 | PLK1 (1.00) | PLK1PLK3NEK2PIK3CDPDGFRB | |
| SCHEMBL19196385 | 0.95 | PLK1 (0.91) | PLK1PLK3NEK2PIK3CDPDGFRB | |
| SCHEMBL25660820 | 0.94 | PLK1 (0.89) | PLK1PLK3NEK2PIK3CDPDGFRB | |
| SCHEMBL2973906 | 0.94 | PLK1 (0.88) | PLK1PLK3NEK2PIK3CDPDGFRB | |
| SCHEMBL2973537 | 0.92 | PLK1 (0.86) | PLK1PLK3NEK2PIK3CDPDGFRB | |
| SCHEMBL4562944 | 0.92 | PLK1 (0.86) | PLK1PLK3NEK2PIK3CDPDGFRB | |
| SCHEMBL4405982 | 0.92 | PLK1 (0.86) | PLK1PLK3NEK2PIK3CDPDGFRB | |
| SCHEMBL13573235 | 0.92 | PLK1 (0.86) | PLK1PLK3NEK2PIK3CDPDGFRB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 43 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2026107349-A1 | HETEROCYCLIC INHIBITORS OF CYCLIN-DEPENDENT KINASES | ANTARES THERAPEUTICS, INC. (US) | 2026-05-21 | — | — | WO | disclosed |
| US-12613245-B2 | Methods for detecting and inhibiting brain metastasis | CORNELL UNIVERSITY (US) | 2026-04-28 | — | — | US | disclosed |
| EP-4695238-A1 | CDK2 INHIBITORS | Blueprint Medicines Corporation (US) | 2026-02-18 | — | — | EP | disclosed |
| US-12545684-B2 | CDK2 inhibitors | BLUEPRINT MEDICINES CORPORATION (US) | 2026-02-10 | — | — | US | disclosed |
| EP-4646413-A1 | SOLID FORMS OF A CDK2 INHIBITOR | Blueprint Medicines Corporation (US) | 2025-11-12 | — | — | EP | disclosed |
| EP-4646414-A1 | CDK2 INHIBITORS | Blueprint Medicines Corporation (US) | 2025-11-12 | — | — | EP | disclosed |
| EP-4646411-A1 | CDK2 INHIBITORS | Blueprint Medicines Corporation (US) | 2025-11-12 | — | — | EP | disclosed |
| EP-4646416-A1 | CDK2 INHIBITORS | Blueprint Medicines Corporation (US) | 2025-11-12 | — | — | EP | disclosed |
| WO-2025224249-A1 | COMPOUNDS THAT MEDIATE PROTEIN DEGRADATION AND METHODS OF USE THEREOF | MONTE ROSA THERAPEUTICS AG (CH) | 2025-10-30 | — | — | WO | disclosed |
| WO-2025072355-A1 | METHODS FOR AND COMPOSITIONS OF NON-PEG BIOCONJUGATES WITH ULTRA-HIGH DRUG-TO-AGENT RATIO | BIOHYBRID SOLUTIONS HOLDINGS, INC. (US) | 2025-04-03 | — | — | WO | disclosed |
| US-20230323466-A1 | DETERMINING CANCER RESPONSIVENESS TO TREATMENT | QUEENSLAND UNIVERSITY OF TECHNOLOGY (AU) | 2023-10-12 | — | — | US | disclosed |
| WO-2023092088-A1 | CDK2 INHIBITORS AND METHODS OF MAKING AND USING SAME | BLUEPRINT MEDICINES CORPORATION (US) | 2023-05-25 | — | — | WO | disclosed |
| US-20230159535-A1 | CDK2 INHIBITORS | BLUEPRINT MEDICINES CORPORATION | 2023-05-25 | — | — | US | disclosed |
| WO-2023092107-A1 | CDK2 INHIBITORS AND METHODS OF MAKING AND USING SAME | BLUEPRINT MEDICINES CORPORATION (US) | 2023-05-25 | — | — | WO | disclosed |
| EP-4181926-A1 | DETERMINING CANCER RESPONSIVENESS TO TREATMENT | Queensland University Of Technology (AU) | 2023-05-24 | — | — | EP | disclosed |
| US-20230001007-A1 | Glycan-Interacting Compounds and Methods of Use | SEAGEN INC. (US) | 2023-01-05 | — | — | US | disclosed |
| WO-2023278326-A1 | CDK2 INHIBITORS | BLUEPRINT MEDICINES CORPORATION (US) | 2023-01-05 | — | — | WO | disclosed |
| WO-2022186512-A1 | PYRIDINYL PYRAZOLE DERIVATIVE OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, AND USE THEREOF | 한양대학교 에리카산학협력단 | 2022-09-09 | — | — | WO | disclosed |
| US-20220170109-A1 | PURITY INDEPENDENT SUBTYPING OF TUMORS (PURIST), A PLATFORM AND SAMPLE TYPE INDEPENDENT SINGLE SAMPLE CLASSIFIER FOR TREATMENT DECISION MAKING IN PANCREATIC CANCER | THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL (US) | 2022-06-02 | — | — | US | disclosed |
| WO-2022098311-A1 | A METHOD FOR PREDICTING RESPONSIVENESS TO PLK1 INHIBITION | NATIONAL UNIVERSITY OF SINGAPORE (SG) | 2022-05-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12613245-B2 | Methods for detecting and inhibiting brain metastasis | EPCAM, CD44, LY96 | PLK1 1504/4885PLK3 3989/4885NEK2 4159/4885 |
| US-20230159535-A1 | CDK2 INHIBITORS | CDK2, CDK20, CDK2AP1 | PLK1 41/4885PLK3 1179/4885NEK2 99/4885 |
| US-12545684-B2 | CDK2 inhibitors | CDK2, CDK4, CDK1 | PLK1 86/4885PLK3 1714/4885NEK2 116/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.